Jim Sang
Overview
Explore the profile of Jim Sang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
815
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Acquaviva J, Smith D, Sang J, Friedland J, He S, Sequeira M, et al.
Mol Cancer Ther
. 2012 Sep;
11(12):2633-43.
PMID: 23012248
Mutant KRAS is a feature of more than 25% of non-small cell lung cancers (NSCLC) and represents one of the most prevalent oncogenic drivers in this disease. NSCLC tumors with...
12.
Foley K, Zhou D, Borella C, Wu Y, Zhang M, Jiang J, et al.
J Pharmacol Exp Ther
. 2012 Jul;
343(2):529-38.
PMID: 22837008
Vascular disrupting agents (VDAs) are an emerging class of therapeutics targeting the existing vascular network of solid tumors. However, their clinical progression has been hampered because of limited single-agent efficacy,...
13.
Shimamura T, Perera S, Foley K, Sang J, Rodig S, Inoue T, et al.
Clin Cancer Res
. 2012 Jul;
18(18):4973-85.
PMID: 22806877
Purpose: We describe the anticancer activity of ganetespib, a novel non-geldanamycin heat shock protein 90 (HSP90) inhibitor, in non-small cell lung cancer (NSCLC) models. Experimental Design: The activity of ganetespib...
14.
Proia D, Sang J, He S, Smith D, Sequeira M, Zhang C, et al.
Invest New Drugs
. 2012 Jan;
30(6):2201-9.
PMID: 22227828
Systemic chemotherapy using two-drug platinum-based regimens for the treatment of advanced stage non-small cell lung cancer (NSCLC) has largely reached a plateau of effectiveness. Accordingly, efforts to improve survival and...
15.
Ying W, Du Z, Sun L, Foley K, Proia D, Blackman R, et al.
Mol Cancer Ther
. 2011 Dec;
11(2):475-84.
PMID: 22144665
Targeted inhibition of the molecular chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel...
16.
Proia D, Foley K, Korbut T, Sang J, Smith D, Bates R, et al.
PLoS One
. 2011 May;
6(4):e18552.
PMID: 21533169
There is accumulating evidence that dysregulated JAK signaling occurs in a wide variety of cancer types. In particular, mutations in JAK2 can result in the constitutive activation of STAT transcription...
17.
Bansal H, Bansal S, Rao M, Foley K, Sang J, Proia D, et al.
Blood
. 2010 Jul;
116(22):4591-9.
PMID: 20651072
The aberrant overexpression of Wilms tumor 1 (WT1) in myeloid leukemia plays an important role in blast cell survival and resistance to chemotherapy. High expression of WT1 is also associated...
18.
Sydor J, Normant E, Pien C, Porter J, Ge J, Grenier L, et al.
Proc Natl Acad Sci U S A
. 2006 Nov;
103(46):17408-13.
PMID: 17090671
Heat shock protein 90 (Hsp90) is an emerging therapeutic target of interest for the treatment of cancer. Its role in protein homeostasis and the selective chaperoning of key signaling proteins...